Marinomed Biotech AG publishes clinical data on the effectiveness of its Carragelose nasal spray in the treatment of hay fever

EQS-News: Marinomed Biotech AG

/ Key word(s): Study results

Marinomed Biotech AG publishes clinical data on the effectiveness of its Carragelose nasal spray in the treatment of hay fever
12.04.2023 / 07:45 CET/CEST

The issuer is solely responsible for the content of this announcement.

Marinomed Biotech AG publishes clinical data on the effectiveness of its Carragelose nasal spray in the treatment of hay fever

  • Carragelose nasal spray shows significant effectiveness in the prophylactic treatment of allergic rhinitis symptoms in the nose
  • Clinical data extend the effectiveness of Carragelose from blocking respiratory viruses to pollen and further prove the barrier function of the product
  • The expansion of the use of Carragelose products from the cold to the allergy season will continue to drive further business growth 

Korneuburg, Austria, 12 April 2023 – Marinomed Biotech AG, listed on the Vienna Stock Exchange (VSE:MARI), today announced further positive results from its clinical study on the anti-allergic properties of its Carragelose nasal spray. The open-label, cross-over, randomized clinical trial conducted at the Vienna Challenge Chamber showed that the nasal spray can significantly decrease the symptoms of allergic rhinitis (hay fever) in patients challenged with their respective allergen. These results show that Carragelose exerts a barrier function that is not only effective in shielding the nasal mucosa from respiratory viruses, but also from pollen. This is particularly important, as patients suffering from allergic rhinitis are also sensitive to viral respiratory infections as these may worsen the underlying allergic disorder.

“These results substantiate the property of Carragelose to form a non-specific barrier, which can protect the nasal mucosa from respiratory viruses or pollen. We can thus extend the use of our product from viral respiratory infections to hay fever. This is not only a major benefit for patients, but also opens up new growth opportunities for us by allowing us to target the global allergy market,” Eva Prieschl-Grassauer, CSO of Marinomed, explained. “Most recently, we have also published clinical data on the decongestant effect of the Sorbitol-containing Carragelose nasal spray. These studies join a series of clinical studies conducted by Marinomed that have been successfully completed with significant results.”

In the clinical trial, healthy adults (18 to 65 years) with a proven grass pollen allergy were continuously exposed to the allergen for three hours to induce allergic symptoms (such as runny nose, blocked nose, sneezing, and itchy nose). To demonstrate prophylactic effectiveness, the treatment with the Carragelose nasal spray was applied before the allergic challenge. Patients with a protective barrier on the nasal mucosa experienced significant lower allergic symptoms compared to patients without (p<0.05). The most prominent reduction was observed for the symptom runny nose which was also significantly decreased (p<0.03). 

About Carragelose®:

Carragelose® is a sulfated polymer from red seaweed and a unique, broadly active virus-blocking compound. It is known as a gentle, effective, and safe prevention and treatment of various viral respiratory infections. Several clinical and preclinical studies have shown that Carragelose® forms a layer on the mucosa that entraps entering viruses, thereby inactivating them, and preventing them from infecting cells. Laboratory and clinical data have shown that Carragelose® can also inactivate SARS-CoV-2.[1],[2] Marinomed is the holder of the IP rights and has licensed Carragelose® for marketing in Europe, North America, Australia, and parts of Asia and Latin America. Marinomed’s portfolio of Carragelose®-containing nasal sprays and oral products can be accessed at, scientific publications on Carragelose® at

About Marinomed Biotech AG:

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of iota-carrageenan. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. The Company is headquartered in Korneuburg, Austria, and is listed on the prime market of the Vienna Stock Exchange (VSE:MARI). For further information, please visit:

 For further inquiries contact:

Marinomed Biotech AG
PR: Lucia Mayr-Harting
T: +43 2262 90300 158
IR: Stephanie Kniep
T: +43 2262 90300 226
International Media Contact
Metrum Communications: Roland Mayrl
T: +43 664 6126228


This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.



12.04.2023 CET/CEST This Corporate News was distributed by EQS Group AG.

show this